Medindia

X

Cadence Pharmaceuticals Receives Complete Response Letter from FDA for Intravenous Acetaminophen NDA

Thursday, February 11, 2010 General News J E 4
Advertisement
-- No new studies requested --

Contacts:

INVESTORS

MEDIA

Cadence Pharmaceuticals, Inc.

WCG

William R. LaRue, SVP and Chief Financial Officer

Aimee Corso

858-436-1400

310-780-2661

blarue@cadencepharm.com

acorso@wcgworld.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
YM BioSciences presents CYT387 and CYT997 data at ...
S
New Solution Simplifies Life's Most Difficult Heal...